USPTO serial 79359336
EVOX THERAPEUTICS
Reviewed by CopyMark Law Group
Status 774
- Filing date
- Status date
- Registration date
- —
- Examiner
- ALLEN, BIANCA LEIGH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EVOX THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, namely, drug delivery agents in the form of exosomes consisting of compounds that facilitate the delivery of a wide range of pharmaceutical preparations; pharmaceutical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use, namely, for the release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, engineered exosomes to deliver pharmaceutical preparations in the nature of protein for genetic therapy; medicine, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations for medical purposes, namely, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosomes, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising a therapeutic target protein-loaded exosome that facilitates the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising exosomes for pharmaceutical purposes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological reagents for medical use, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; mixed biological preparations for medical purposes, namely, for the prevention and treatment of infectious diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or infectious diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies, namely, mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; all of the foregoing excluding such goods in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes | ACTIVE | — |
| 042 | Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; all of the foregoing excluding such services in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks owned by Evox Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named EVOX THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 21, 2025 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 21, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| May 21, 2025 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| May 20, 2025 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| May 20, 2025 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Jan 30, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 26, 2024 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Dec 23, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 20, 2024 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Dec 20, 2024 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 20, 2024 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Nov 25, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 20, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 20, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 20, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 7, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 14, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2023 | CRSN | CORRECTION SENT TO IB | — |
| Nov 27, 2023 | CRCR | CORRECTION CREATED FOR IB | — |
| Oct 31, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 5, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 4, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 24, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 23, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 3, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2022 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |